News | Radiopharmaceuticals and Tracers | September 07, 2016

First Prostate Cancer Patients Imaged With Axumin (Fluciclovine F-18) Tracer at Atlanta's Northside Hospital

Recently FDA-approved PET imaging agent for patients with suspected biochemically recurrent prostate cancer now also in use at additional medical centers

Axumin, fluciclovine F-18 injection, first injection, Northside Hospital Atlanta

September 7, 2016 — Blue Earth Diagnostics announced that the first post-U.S. Food and Drug Administration (FDA) approval, commercial administrations of AxuminTM (fluciclovine F 18) injection occurred recently at Northside Hospital of Atlanta. Axumin is a novel molecular imaging agent indicated for use in positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood levels of prostate specific antigen (PSA) following prior treatment. It was recently approved by the FDA and is the first FDA-approved F-18 PET imaging agent indicated for use in patients with suspected recurrent prostate cancer.

“To date, we have had few imaging tools available for the evaluation of men with biochemically recurrent prostate cancer,” said William C. Lavely, M.D., nuclear medicine specialist, Northside Radiology Associates. “The approval of F-18 fluciclovine (Axumin) gives us an effective molecular imaging tool to evaluate these patients and assist clinicians in directing further management. Our initial experience is positive, demonstrating abnormal uptake in locations of potential metastatic prostate cancer. In my opinion, this prostate cancer PET agent, its clinical use for the evaluation of recurrent prostate cancer, and the additional information it provides for developing patient management plans has the potential to lead to better outcomes in men with recurrent prostate cancer. Further studies are necessary to determine these potential benefits.”

Axumin is commercially available through the national radiopharmacy network of Blue Earth Diagnostics’ exclusive U.S. commercial manufacturer and distributor, Siemens’ PETNET Solutions. Initial commercial production of Axumin is underway at certain regional radiopharmacies, and increasingly broader availability is planned in coming months.

Axumin was developed to enable visualization of the increased amino acid transport that occurs in many cancers, including prostate cancer. It consists of a synthetic amino acid that is preferentially taken up by prostate cancer cells compared with surrounding normal tissues, and is labeled with the radioisotope F18 for PET imaging.

For more information: www.blueearthdx.com 

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...